aBLA Filing Intelligence & Biosimilar Opportunity

Vabysmo

Faricimab-Svoa

Ophthalmic agent

Intravitreal Injectable

Approval Date

28-Jan-22

Data Exclusivity Expiry

28-Jan-26

Market Exclusivity Expiry

28-Jan-34

Commercial snapshot

Market performance & projections

Revenue ($M)

4939

CAGR (%)

0.0809

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

5384

2027

5995

2028

6449

2029

6742

2030

6966

2031

7095

2032

7223

Molecule profile

Details & specifications

Molecule

Faricimab-Svoa

Innovator

GENENTECH, INC.

Dosage Form

Intravitreal Injectable

Strength

120 mg/mL

Therapeutic Category

Ophthalmic agent

Usage

To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.